Cancer Patient T Cells Genetically Targeted to Prostate-Specific Membrane Antigen Specifically Lyse Prostate Cancer Cells and Release Cytokines in Response to Prostate-Specific Membrane Antigen

Neoplasia

Volumn 1, Issue 2, 1999, Pages 123-127

  Gong, Michael C ^a   Latouche, Jean Baptiste ^a   Krause, Anja ^a   Heston, Warren D W ^a   Bander, Neil H ^a   Sadelain, Michel ^a,b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Costimulation; Gene therapy; Immunotherapy; Prostate cancer; Retroviral mediated gene transfer

Indexed keywords

CARBOXYPEPTIDASE; CD28 ANTIGEN; CYTOKINE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; HYBRID PROTEIN; MEMBRANE ANTIGEN;

AGED; ANIMAL; ARTICLE; BIOSYNTHESIS; CELL SEPARATION; CELL STRAIN 3T3; COCULTURE; CYTOTOXIC T LYMPHOCYTE; EPITHELIUM CELL; FIBROBLAST; FLOW CYTOMETRY; GENE TRANSFER; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MOUSE; PROSTATE TUMOR; RETROVIRUS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

3T3 CELLS; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD28; ANTIGENS, SURFACE; CARBOXYPEPTIDASES; CELL SEPARATION; COCULTURE TECHNIQUES; CYTOKINES; EPITHELIAL CELLS; FIBROBLASTS; FLOW CYTOMETRY; GENE TRANSFER TECHNIQUES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MICE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033139686     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900018     Document Type: Article

References (16)

1. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, and Reichert CM (1985). Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313, 1485-1492.
2. Greenberg PD (1991). Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49, 281-355.
3. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, and Levitsky H (1998). Induction of antigen-specific T cell energy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 95, 1178-1183.
4. Eshhar Z, Bach N, Fitzer-Attas CJ, Gross G, Lustgarten J, Waks T, and Schindler DG (1996). The T-body approach: potential for cancer immunotherapy. Springer Semin Immunopathol 18, 199-209.
5. Krause A, Guo H-F, Latouche J-B, Tan C, Cheung N-KV, and Sadelain M (1998). Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 188, 619-626.
6. Israeli RS, Powell CT, Corr JG, Fair WR, and Heston WDW (1994). Expression of the prostate-specific membrane antigen. Cancer Res 54, 1807-1811.
7. Wright GL, Haley C, Beckett ML, and Schellhammer PF (1995). Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urologic Oncology 1, 18-28.
8. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, and Bander NH (1997). Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57, 3629-3634.
9. Gallardo HF, Tan C, Dry D, and Sadelain M (1997). Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 90, 952-957.
10. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, and Ochoa AC (1992). Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258, 1795-1798.
11. Zier KS, and Gansbacher B (1995). The impact of gene therapy on T cell function in cancer. Hum Gene Ther 6, 1259-1264.
12. Lenschow DJ, Walunas TL, and Bluestone JA (1996). CD28/B7 system of T cell costimulation. Annu Rev Immunol 14, 233-258.
13. Allison JP, Hurwitz AA, and Leach DR (1996). Manipulation of costimulatory signals to enhance antitumor T cell responses. Curr Opin Immunol 23, 682-686.
14. Szabolcs P, Gallardo HF, Ciocon D, Sadelain M, and Young J (1997). Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. Blood 90, 2160-2167.
15. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J, and the German Cancer Aid 17-1A Study Group (1994). Randomised trial of monoclonal antibody for adjuvant therapy of resected Duke's C colorectal carcinoma. Lancet 343, 1177-1183.
16. Cheung NK, Kushner BH, Yeh SDJ, and Larson SM (1998). 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: A phase II study. Int J Oncol 12, 1299-1306.